COMMUNIQUÉS West-GlobeNewswire

Exagen to Announce Second Quarter Financial Results on August 4, 2026
21/07/2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market [...]
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
21/07/2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release [...]
Philips receives FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor
21/07/2026
July 21, 2026 New sensor advances pulse oximetry reliability for diverse patient populations through innovation and rigorous validation. Cambridge, MASS – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health [...]
NeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHD
21/07/2026
U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026 Gen 2 Monarch device provides an enhanced patient experience while delivering clinically proven therapeutic stimulation of the trigeminal [...]
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
21/07/2026
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate AI agent platform prepares for commercial launch while SPC-15 regulatory program advances [...]
Merakris Therapeutics Awarded NIH Direct-to-Phase II SBIR Grant to Advance MTX-001 for Diabetic Foot Ulcers
21/07/2026
Award supports a two-year project expected to provide up to $2.2 million in non-dilutive funding while expanding Merakris' clinical-stage pipeline into a second major chronic wound indication RESEARCH TRIANGLE PARK, N.C [...]
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
21/07/2026
Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: [...]
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
21/07/2026
Company CEO has been a featured presenter at several recent industry events on the emergence of endovascular robotics as expert speaking opportunities raising profile of the Company throughout medtech market HINGHAM, [...]
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
21/07/2026
A Promising Strategy for Improving Production for Applications in Biotechnology Research MELBOURNE, Australia, July 21, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
21/07/2026
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing [...]
Standard Dental Labs Announces Acquisition Capital Strategy to Support Next Phase of Florida Expansion
21/07/2026
ORLANDO, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) ("SDL" or the "Company"), a consolidator of dental laboratories throughout Florida, today announced that its Board of Directors [...]
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
21/07/2026
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the [...]
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
21/07/2026
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- [...]
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
21/07/2026
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE [...]
Applied Biologics Initiates Multi-Center Real-World Outcomes Study of XWRAP® Across Chronic Wound Types
21/07/2026
SCOTTSDALE, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21/07/2026
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- [...]
Kraig Biocraft Laboratories CEO Kim Thompson Featured in Just Style, a Leading Global Apparel Industry Trade Publication
21/07/2026
Interview Spotlights Company's Commercial-Scale Production Progress and Path to Transforming the Global Textile Industry ANN ARBOR, Mich., July 21, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
21/07/2026
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today [...]
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
21/07/2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and [...]

Pages